Drug Combinations as the New Standard for Melanoma Treatment
- 20 October 2016
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 17 (12) , 61
Abstract
Advanced melanoma is related to a very grim prognosis and fast progression. Until recently, there has been no indicated treatment that would affect the disease’s outcome. However, the progress in immunotherapy and molecular therapy has significantly changed the unfavourable prognosis of melanoma progression and its short survival rate. Both approaches have improved patients’ outcomes and provided renewed hope for successful treatment. Moreover, in order to further enhance patients’ outcomes and to avoid mechanisms of tumour resistance, investigators attempted a combined approach. Targeted therapy combinations allowed a better response rate and progression-free survival than monotherapy with one of the agents. Another promising combination, but with limiting toxicities, is a concurrent immuno- and molecular-targeted therapy. It is suspected that complimentary usage of these drugs may lead to synergism, providing robust and quick tumour responses as well as long-lasting effects. Results of currently ongoing clinical trials that investigate combination strategies in melanoma are expected to provide more mature data about the effectiveness and the safety profile of those therapies. Until more robust results of these studies occur, the best management of advanced and metastatic melanoma is immunotherapy with anti-PD1 drugs or targeted therapy with concomitant BRAF and MEK inhibitor. However, which of these two options should be used first is still under discussion.Keywords
This publication has 53 references indexed in Scilit:
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyThe Lancet Oncology, 2014
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guidelineEuropean Journal of Cancer, 2010
- Surgery and radiotherapy in the treatment of cutaneous melanomaAnnals of Oncology, 2009
- Epidemiology of invasive cutaneous melanomaAnnals of Oncology, 2009
- Treatments for metastatic melanoma: Synthesis of evidence from randomized trialsCancer Treatment Reviews, 2007
- The Management of Head and Neck MelanomaCurrent Problems in Surgery, 2006
- Mutations of the BRAF gene in human cancerNature, 2002
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001